Table 2.

Inclusion and exclusion criteria

	GOGO and SLOWGO Arms	NOGO Arm
Inclusion criteria
Patients ≥70 years of age	+	+
Histologically or cytologically confirmed metastatic adenocarcinoma of the pancreas.	+	+
No prior chemotherapy (except fluoruracil or gemcitabine in an adjuvant setting at least > 6 months prior enrollment).	+	+
Cooperation and willingness to complete all aspects of the study	+	+
Written informed consent to participate in the study	+	+
At least one measurable lesion of disease according to RECIST 1.1 criteria.	+
Adequate end organ function (renal function: serum creatinine ≤1.5 × ULN or GFR≥30mL/min, hematopoietic function: white blood cell (WBC) count ≥3000/μL, absolute neutrophil count (ANC)≥1500/μL, platelets ≥105/μL, hemoglobin level>9.0g/dL, liver function: total bilirubin ≤1.5 × ULN, AST / ALT ≤3.0 × ULN)	+
Exclusion criteria
Patient has received any other investigational product within 28days prior study entry	+	+
Patient is < 5years free of another primary malignancy (except: not currently clinically significant nor requiring active intervention)	+	+
Patient with any significant history of non-compliance to medical regimens or with inability to grant reliable informed consent	+	+
Any psychiatric illness that would affect the patient’s ability to understand the demands of the clinical trial	+	+
Parallel participation in another clinical trial or participation in another clinical trial within the last 30days or 7 half-lifes of a study medication, whichever is of longer duration, prior study start	+	+
Patient has a severe and/or uncontrolled medical disease (i.e. uncontrolled active infection, uncontrolled hypertension/ diabetes or cardiac disease).	+
Hypersensitivity against gemcitabine or nab-paclitaxel.	+
Major surgery ≤28 days prior to study entry.	+
Patient has a known diagnosis of human immunodeficiency virus (HIV) infection.	+